Skip to main content

Trends in Single-Dose Doxycycline for Lyme Disease Prophylaxis in the United States: A Third Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
doxycycline
Description

Lyme disease can be prevented by taking one dose of doxycycline (200 mg or 4.4 mg/kg for persons <45 kg) when administered within 72 hours after a high‐risk tick bite. To shed light on patterns of Lyme disease post‐exposure prophylaxis (PEP) in the United States, we characterized the frequency and patterns of single dose doxycycline over time, and described characteristics of individuals with these dispensings in the Sentinel Distributed Database (SDD). 

This a follow up to a previous analysis to update the study period and incorporate patients with Medicaid coverage. This analysis contains three reports:

  • Report 1 contains patients with Medicaid coverage.
  • Report 2 contains patients with claims coverage.
  • Report 3 contains patients with Medicaid coverage and claims coverage. 

The study period includes data from January 1, 2016 to December 31, 2020. We distributed this request to five Sentinel Data Partners on December 2, 2024. 

Deliverables (3)
Sentinel Modular Program Report: Trends in Single-Dose Doxycycline for Lyme Disease Prophylaxis in the United States: A Third Descriptive Analysis, Report 1 Sentinel Modular Program Report: Trends in Single-Dose Doxycycline for Lyme Disease Prophylaxis in the United States: A Third Descriptive Analysis, Report 2 Sentinel Modular Program Report: Trends in Single-Dose Doxycycline for Lyme Disease Prophylaxis in the United States: A Third Descriptive Analysis, Report 3
Additional Details
FDA Center
CDER
Time Period
January 1, 2016 - December 31, 2020
Analysis Type
Descriptive
Population / Cohort
Individuals 19 years of age and younger
Data Sources
Sentinel Distributed Database (SDD)
Related Links
Sentinel Drug Analysis: Trends in Single-Dose Doxycycline for Lyme Disease Prophylaxis in the United States: A Descriptive Analysis
Sentinel Drug Analysis: Trends in Single-Dose Doxycycline for Lyme Disease Prophylaxis in the United States: A Second Descriptive Analysis